374 related articles for article (PubMed ID: 18713946)
1. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.
Sander S; Bullinger L; Klapproth K; Fiedler K; Kestler HA; Barth TF; Möller P; Stilgenbauer S; Pollack JR; Wirth T
Blood; 2008 Nov; 112(10):4202-12. PubMed ID: 18713946
[TBL] [Abstract][Full Text] [Related]
2. Repressing the repressor: a new mode of MYC action in lymphomagenesis.
Sander S; Bullinger L; Wirth T
Cell Cycle; 2009 Feb; 8(4):556-9. PubMed ID: 19197161
[TBL] [Abstract][Full Text] [Related]
3. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
[TBL] [Abstract][Full Text] [Related]
4. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
[TBL] [Abstract][Full Text] [Related]
5. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.
Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP
Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma.
Zhang X; Zhang X; Wang T; Wang L; Tan Z; Wei W; Yan B; Zhao J; Wu K; Yang A; Zhang R; Jia L
Cancer Lett; 2018 Jul; 426():98-108. PubMed ID: 29653269
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
[TBL] [Abstract][Full Text] [Related]
8. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
Dang X; Ma A; Yang L; Hu H; Zhu B; Shang D; Chen T; Luo Y
Cancer Genet; 2012 Mar; 205(3):113-23. PubMed ID: 22469510
[TBL] [Abstract][Full Text] [Related]
10. C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells.
Guo P; Nie Q; Lan J; Ge J; Qiu Y; Mao Q
Biochem Biophys Res Commun; 2013 Nov; 441(1):186-90. PubMed ID: 24140063
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway.
Bueno MJ; Gómez de Cedrón M; Gómez-López G; Pérez de Castro I; Di Lisio L; Montes-Moreno S; Martínez N; Guerrero M; Sánchez-Martínez R; Santos J; Pisano DG; Piris MA; Fernández-Piqueras J; Malumbres M
Blood; 2011 Jun; 117(23):6255-66. PubMed ID: 21478429
[TBL] [Abstract][Full Text] [Related]
12. Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma.
Oduor CI; Kaymaz Y; Chelimo K; Otieno JA; Ong'echa JM; Moormann AM; Bailey JA
BMC Cancer; 2017 Nov; 17(1):761. PubMed ID: 29132323
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis.
Wong CF; Tellam RL
J Biol Chem; 2008 Apr; 283(15):9836-43. PubMed ID: 18281287
[TBL] [Abstract][Full Text] [Related]
14. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
Onnis A; De Falco G; Antonicelli G; Onorati M; Bellan C; Sherman O; Sayed S; Leoncini L
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20930934
[TBL] [Abstract][Full Text] [Related]
15. MiR-26a Mediates Ultraviolet B-Induced Apoptosis by Targeting Histone Methyltransferase EZH2 Depending on Myc Expression.
Zhang T; Qian H; Hu C; Lu H; Li JB; Wu YF; Li W
Cell Physiol Biochem; 2017; 43(3):1188-1197. PubMed ID: 28977801
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.
Zhao X; Lwin T; Zhang X; Huang A; Wang J; Marquez VE; Chen-Kiang S; Dalton WS; Sotomayor E; Tao J
Leukemia; 2013 Dec; 27(12):2341-50. PubMed ID: 23538750
[TBL] [Abstract][Full Text] [Related]
17. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
18. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.
Alajez NM; Shi W; Hui AB; Bruce J; Lenarduzzi M; Ito E; Yue S; O'Sullivan B; Liu FF
Cell Death Dis; 2010 Oct; 1(10):e85. PubMed ID: 21368858
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
[TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
